$SGEN News Article - Seattle Genetics and Astellas Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
https://marketwirenews.com/news-releases/seat...21096.html